Form 4: Aclaris Therapeutics Director Christopher P. Molineaux Reports Stock Option and Restricted Stock Unit Grants

Director Christopher P. Molineaux reports the acquisition of stock options and restricted stock units in Aclaris Therapeutics, Inc.

Summary

• Christopher P. Molineaux, a director of Aclaris Therapeutics, Inc., reported the acquisition of stock options and restricted stock units on June 6, 2024.
• The stock options grant consists of 15,750 shares with an exercise price of $1.03 per share, vesting in twelve equal monthly installments starting July 6, 2024.
• Molineaux also received 4,793 restricted stock units, each representing a contingent right to receive one share of common stock, vesting on June 6, 2025.
• These grants were made under the issuer's ninth amended and restated non-employee director compensation policy.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices for a company director, aligning interests with shareholders.

Positives

• The grants of stock options and restricted stock units align the director's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Grants of stock options and restricted stock units are common practice for compensating directors and aligning their interests with shareholders in the biotechnology industry.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are standard practice in the biotech industry to attract and retain qualified board members.
• The size of the grant is likely benchmarked against peer companies of similar market capitalization and stage of development.
• Companies like Madrigal Pharmaceuticals and Viking Therapeutics also utilize similar equity-based compensation for their directors.

Stakeholder Impact

• The grants align the director's interests with shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates